Jazz Pharmaceuticals

Star Therapeutics Appoints Matthew Fust as Independent Director and Board Audit Chair

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Pharmaceutical, Health, Star, Audit committee, Westlake Village, California, Therapy, Biology, University, Jazz Pharmaceuticals, Alza, MBA, MD, Growth, Doctor of Philosophy, Business, Onyx Pharmaceuticals, Pharmaceutical industry, Management

Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Matthew Fust, a veteran finance executive in the life sciences industry, to its Board of Directors.

Key Points: 
  • Star Therapeutics , a biotechnology company interrogating novel biology to develop life-changing therapies, today announced the appointment of Matthew Fust, a veteran finance executive in the life sciences industry, to its Board of Directors.
  • Mr. Fust will also serve as chair of the Audit Committee.
  • “We are pleased to welcome Matthew as a member of our board at this exciting time of growth,” said Adam Rosenthal, PhD, Chief Executive Officer and Founder of Star Therapeutics.
  • “Matthew is an industry veteran with numerous successes in his career,” said Beth Seidenberg, MD, Founding Managing Director at Westlake Village BioPartners.

FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)

Retrieved on: 
Tuesday, November 21, 2023
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Lancet, National Cancer Institute, Jazz Pharmaceuticals, Takeda, CRC, Specialty pharmacy, Anti-VEGF, VEGFR-3, Mortality, Patient, Pharmacy, Large intestine, VEGF, Caregiver, PharMerica, Colorectal cancer, Cancer, Diagnosis, Metastasis, Death, Hospital, Irinotecan, JAMA, Pharmaceutical industry

Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.

Key Points: 
  • Fruzaqla™ is a selective oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3, which play a pivotal role in blocking tumor angiogenesis.
  • Colorectal cancer is the fourth most frequent diagnosed cancer and second leading cause of death in the U.S.
  • Fruquintinib vs Placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicenter, randomized double blind, phase 3 study.
  • Effect of fruquintinib vs Placebo on overall survival in patients with previously treated metastatic colorectal cancer.

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, CNS, Ion channel, Noetics, Membrane, Therapy, Gene, Myenteric plexus, DSM-IV codes, Jazz Pharmaceuticals, Eurosport 1, Patient, Medicine, Movement, Central nervous system disease, Drug discovery, Pharmaceutical industry, Vaccine, Jazz

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Key Points: 
  • Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.
  • Autifony will lead drug discovery and preclinical development activities on the two targets.
  • Subsequent to successful completion of such preclinical development, Jazz will lead all clinical development, manufacturing and regulatory activities and commercialization.
  • Under the terms of the agreement, Autifony will receive an upfront payment from Jazz and is eligible to receive development, regulatory and commercial milestone payments across the two programmes.

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Retrieved on: 
Friday, December 8, 2023
Trastuzumab, Research, Progression-free survival, RECIST, Fulvestrant, Breast cancer, Jazz Pharmaceuticals, Patient, PFS, Part, Corr, DOR, MBC, DCR, Pertuzumab, HER2, Cancer, Vall d'Hebron University Hospital, BS 5839 Part 1, Metastasis, HR, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Patients treated with the combination regimen received a median of four prior systemic regimens in the metastatic setting (range, 1-12).
  • Recommended doses of the zanidatamab plus palbociclib and fulvestrant combination therapy were determined in Part 1 of the study.
  • Patients treated with the combination regimen achieved a cORR of 35% and DCR of 91%.

Illuminate Hypersomnia Initiative Shines Light on What It's Like to Live with Idiopathic Hypersomnia

Retrieved on: 
Thursday, December 7, 2023
Organization, Food, Human voice, Therapy, IH, Patient, Jazz Pharmaceuticals, Fatigue, Partner, Idiopathic hypersomnia, Hatred, Diagnosis, PALM, Doctor of Philosophy, News, Pharmaceutical industry, Nursing, Takeda

WEST PALM BEACH, Fla., Dec. 7, 2023 /PRNewswire/ -- The Sleep Consortium, in collaboration with sleep-related patient advocacy organizations worldwide, announces the Illuminate Hypersomnia initiative, a groundbreaking effort to highlight the lived experience of idiopathic hypersomnia (IH). This initiative aims to fully describe the impact of IH on the lives of those affected, their current management strategies, and the treatment benefits that matter most to them as new therapies are developed.

Key Points: 
  • The meeting will be streamed live, bringing members of the global IH community together to share their experiences and perspectives.
  • The Illuminate Hypersomnia initiative also aims to expand collaboration and support within the IH community to help individuals learn from and empower one another.
  • "Our mission with the Illuminate Hypersomnia initiative is clear: bring to light the hidden struggles of idiopathic hypersomnia and unite in the quest for better treatments," remarked CEO of Sleep Consortium Lindsay Jesteadt, PhD.
  • Organizations generously supporting the Illuminate Hypersomnia initiative with unrestricted educational grants include Alkermes, Avadel Pharmaceuticals, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, and Zevra Therapeutics.

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

Retrieved on: 
Thursday, November 30, 2023
Bone marrow, Trae Elston, Research, Safety, ASH, NACLC, Fulvestrant, Acute leukemia, International Association, MD Anderson Cancer Center, LBL, Breast cancer, ESMO, Jazz Pharmaceuticals, Patient, ASCO, MBC, Acute lymphoblastic leukemia, Conference, NSAA, Abstract, HER2, Lung cancer, Jazz, Society, ALL, HR, Pharmaceutical industry

DUBLIN, Nov. 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9; 11 abstracts at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12; and two abstracts at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC) from December 1-3. New data include updated findings from a Phase 2a trial of the investigational HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free option for HER2+/ HR+ metastatic breast cancer (mBC).

Key Points: 
  • New data include updated findings from a Phase 2a trial of the investigational HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free option for HER2+/ HR+ metastatic breast cancer (mBC).
  • "SABCS will also feature data from a trial of zanidatamab in neoadjuvant breast cancer.
  • An investigator-sponsored (MD Anderson Cancer Center) SABCS poster presentation featuring results of a Phase 1 trial evaluating neoadjuvant zanidatamab in patients with stage 1 node-negative HER2+ breast cancer as a single-agent chemotherapy-free option.
  • Treatment‐related adverse events (TRAEs) ≥ grade 3 occurred in 126/228 (55%) patients with no TRAEs that led to death.1
    The Jazz and partner-supported presentations at SABCS 2023 are:

Under 1% of unicorns are profiting at scale with true business success despite $1 billion-plus valuations--Bain & Company analysis

Retrieved on: 
Thursday, November 9, 2023
Jazz Pharmaceuticals, Social media, Unicorn, Meta, BioNTech, Daqo New Energy, Tesla, Bain & Company, Interview, Uber, Biotechnology, ServiceNow, Bank, Pharmaceutical industry, Mail, Airbnb, Palo Alto Networks

Of some 225,000 companies founded during the past 20 years, only around 2,500 have achieved $1 billion market valuations (including public and private businesses).

Key Points: 
  • Of some 225,000 companies founded during the past 20 years, only around 2,500 have achieved $1 billion market valuations (including public and private businesses).
  • And just 15 companies generate more than $1 billion in cash and revenues – a tiny subset of unicorns that have transformed their marketplaces.
  • The 15 established and scale insurgent businesses that have achieved this status make up just 0.7% of the total number of unicorns.
  • They are focused on rapidly scaling a powerful customer franchise and building a cash generative business that can sustain itself.

US-Cannabis Market is to grow by USD 46.90 billion between 2022 - 2027 | Rising millennial population Drive Demand for the market - Technavio

Retrieved on: 
Thursday, November 9, 2023
Aurora, Cannabis, Timeline of cannabis laws in the United States, Food, CBD, Millennials, ROW, Research, Geography, Software, Research report, Medical cannabis, Growth, Medical Marijuana, Inc., NIDA, Jazz Pharmaceuticals, MM, USD, National Institute on Drug Abuse, Compound annual growth rate, Drug, Retail

Millennials, the largest US population, are driving this growth with their enthusiasm for diverse cannabis products, particularly for recreational use.

Key Points: 
  • Millennials, the largest US population, are driving this growth with their enthusiasm for diverse cannabis products, particularly for recreational use.
  • Growth Prospects of the US Cannabis Market in Emerging Markets include:
    The emphasis on the medical potential of cannabis is propelling a surge in research and development.
  • As millennials drive demand, medical research advances and innovative trends emerge, the market is positioned for unparalleled expansion.
  • Cannabis-infused Edible Products Market: The global cannabis-infused edible products market share is expected to increase by USD 5,638.94 million from 2022 to 2027, and the market's growth momentum will accelerate at a CAGR of 19.32%.

Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers

Retrieved on: 
Tuesday, November 7, 2023
Bispecific monoclonal antibody, Jazz Pharmaceuticals, MD Anderson Cancer Center, Research, Bone marrow, American Society of Clinical Oncology, HER2, Monroe Dunaway Anderson, Society, Tissue-agnostic cancer drug, Jazz, Cancer, Annual general meeting, University, Therapy, Patient, ASCO, Medical imaging

DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

Key Points: 
  • DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
  • Jazz and MD Anderson will establish a joint steering committee to oversee the collaboration, which will fund multiple studies over its five-year term.
  • This effort builds upon a previous strategic collaboration between Jazz and MD Anderson focused on hematologic malignancies.
  • Zanidatamab has compelling anti-tumor activity across a broad range of HER2-positive cancers," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals.

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023

Retrieved on: 
Wednesday, October 25, 2023
Jazz Pharmaceuticals, Interest, Nightclub, Broadcasting

DUBLIN, Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.

Key Points: 
  • DUBLIN, Oct. 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.
  • ET / 9:30 p.m. GMT to discuss 2023 third quarter financial results and provide a business and financial update.
  • Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.